Form 4: BeiGene Director Wang Xiaodong Reports Share Sales Under 10b5-1 Plan
SEC Form 4
Wang Xiaodong, a director at BeiGene, Ltd., reported the sale of American Depositary Shares (ADS) on February 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 4, 2025, Wang Xiaodong, a director of BeiGene, Ltd., reported the sale of American Depositary Shares (ADS).
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 12, 2024.
- A total of 41,760 ADS were acquired through option exercise at a price of $6.5.
- Simultaneously, 32,661 ADS were sold at a weighted average price of $222.998, 1,519 ADS at $224.1816, 2,161 ADS at $225.2686, 17,805 ADS at $226.3504, 9,776 ADS at $226.9979, 1,400 ADS at $228.0421.
- After these transactions, Wang Xiaodong directly owns 11,176 ADS.
- Wang Xiaodong also indirectly owns 5,240,882 ordinary shares, 1,025,063 ordinary shares through a family trust, 4,058,998 ordinary shares through Wang Investment LLC, and 50 ordinary shares held by their spouse.
- Wang Xiaodong also holds options to purchase 2,171,527 ordinary shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Future Outlook
The reporting person will likely continue to execute sales under the 10b5-1 trading plan.
Industry Context
Share sales by insiders are a common occurrence, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to diversify their holdings while avoiding concerns about trading on non-public information.
Comparison to Industry Standards
- Comparing Wang Xiaodong's transactions to similar filings by directors at comparable biotech companies would provide context on the scale and frequency of insider trading.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals could serve as benchmarks for assessing the magnitude of these transactions relative to the company's market capitalization and the director's overall holdings.
- The use of a 10b5-1 trading plan is a standard practice among corporate insiders to manage their stock sales in a compliant manner.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- However, the pre-planned nature of the sales mitigates concerns about insider information influencing the transactions.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 02/04/2025 | Date of transactions (acquisition and disposition of shares) |
| 02/06/2025 | Date of signature of the Form 4 filing |
| 07/19/2025 | Expiration date of the share option |
Keywords
BeiGene, Wang Xiaodong, ADS, American Depositary Shares, Rule 10b5-1, Share Sales, Director, Beneficial Ownership, Ordinary Shares, Share Option
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.